Valeant Pharmaceuticals International (VRX) 116.16 $VRX
ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Valeant Pharmaceuticals International, Inc. and Encourages Shareholders to Contact the Firm
Business Wire - 28 mins ago
Goldberg Law PC (www.Goldberglawpc.com) announces that a class action lawsuit has been filed in the United States District Court for the District of New Jersey against Valeant Pharmaceuticals International, Inc. ("Valeant" or the "Company"
(NYSE: VRX), for alleged violations of the federal securities laws. Investors who purchased or otherwise acquired shares between February 23, 2015 and October 20, 2015, are advised to contact the firm in advance of the lead plaintiff motion deadline.
VRX: 116.16 (+6.29), VRX.TO: 152.69 (+8.64)
Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Valeant Pharmaceuticals International, Inc. (VRX)
GlobeNewswire - 44 mins ago
Gainey McKenna & Egleston announces that a class action lawsuit has been filed in the United States District Court for the District of New Jersey on behalf of all persons or entities that purchased the securities of Valeant Pharmaceuticals International, Inc. ("Valeant" or the "Company" (NYSE:VRX) between February 23, 2015 and October 20, 2015 (the "Class Period" , alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the "Complaint" .
VRX: 116.16 (+6.29), VRX.TO: 152.69 (+8.64)
EQUITY ALERT: Rosen Law Firm Expands Class Period in Securities Class Action Lawsuit Against Valeant Pharmaceuticals International, Inc.
Business Wire - 2 hrs 37 mins ago
Rosen Law Firm, a global investor rights law firm, announces that it has filed a class action lawsuit on behalf of purchasers of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) securities from February 28, 2014 through October 21, 2015, both dates inclusive (the "Class Period" . The lawsuit seeks to recover damages for Valeant investors under the federal securities laws.
VRX: 116.16 (+6.29), VRX.TO: 152.69 (+8.64)
Bernstein Liebhard LLP Investigates Claims on Behalf of Those Who Invested in Valeant Pharmaceuticals International, Inc.
PR Newswire - Fri Oct 23, 4:00PM CDT
Bernstein Liebhard LLP is investigating whether Valeant Pharmaceuticals International, Inc. ("Valeant" or the "Company" (NYSE: VRX) violated the federal securities laws by making misstatements concerning the Company's business. The investigation concerns whether Valeant and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
VRX: 116.16 (+6.29), VRX.TO: 152.69 (+8.64)
Few Can Grab Big-Cap Coattails
at The Street - Fri Oct 23, 3:15PM CDT
Another good day, but it's a narrow market.
AMZN: 599.03 (+35.12), GE: 29.51 (-0.07), VRX: 116.16 (+6.29), AXP: 74.59 (+2.09), SKX: 31.64 (-14.55), VFC: 63.75 (-9.46), WHR: 145.90 (-13.91), T: 33.74 (-0.22), SPY: 207.51 (+2.25), IBM: 144.68 (+0.59), TGT: 72.94 (-4.17), SRCL: 120.31 (-28.73), MCD: 112.59 (+1.72), GM: 35.95 (+0.53), GOOGL: 719.33 (+38.19), MSFT: 52.87 (+4.84)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Valeant Pharmaceuticals International, Inc. of Pendency of Class Action Lawsuit and a Lead Plaintiff Deadline of December 21, 2015 - VRX
GlobeNewswire - Fri Oct 23, 3:06PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
VRX: 116.16 (+6.29), VRX.TO: 152.69 (+8.64)
It's Been a Great Week, but Don't Get Cocky
at The Street - Fri Oct 23, 2:30PM CDT
There's some good news in the headlines, but potential threats lurk.
AMZN: 599.03 (+35.12), VRX: 116.16 (+6.29), SONC: 27.74 (+0.04), IBM: 144.68 (+0.59), P: 12.39 (-6.80), FB: 102.19 (+2.52), WYNN: 67.60 (+4.42), DIS: 113.09 (-0.16), MCD: 112.59 (+1.72), GOOGL: 719.33 (+38.19), WDC: 69.34 (-0.62), SNDK: 78.37 (+1.28)
Valeant Shares on a Slide, To Host Emergency Board Meeting
Zacks Equity Research - Zacks Investment Research - Fri Oct 23, 2:20PM CDT
Investors have raised questions regarding the accounting and business practices of Valeant (VRX), particularly its relationship with specialty pharmacies.
VRX: 116.16 (+6.29), NVO: 55.72 (+2.07), ANAC: 102.90 (+10.87)
Valeant Pharmaceuticals (VRX) Stock Rebounds Ahead of Conference Call
at The Street - Fri Oct 23, 12:31PM CDT
Valeant Pharmaceuticals (VRX) stock is rallying in midday trading on Friday, ahead of a conference call on Monday addressing Citron Research's allegations.
VRX: 116.16 (+6.29)
Clarification: Earns-Valeant Pharmaceuticals
AP - Fri Oct 23, 12:01PM CDT
QUEBEC, Quebec (AP) — An Oct. 19 story on Valeant Pharmaceuticals International Inc.'s quarterly earnings generated by Automated Insights failed to mention the month in which the company's current quarter ends. It ends in December.
VRX: 116.16 (+6.29), VRX.TO: 152.69 (+8.64)
Shareholder Alert: Morganti Legal Announces Investigation of Valeant Pharmaceuticals International Inc. (VRX)
CNW Group - Fri Oct 23, 10:57AM CDT
Morganti Legal, a cross-border law firm focused on representing investors, has commenced an investigation into potential violations of securities laws by Valeant Pharmaceuticals International Inc. (TSX and NYSE: "VRX" in respect of allegations that Valeant may have released materially misleading business information to the investing public including potentially inflating revenues by recording intercompany sales in its revenue figures.
VRX: 116.16 (+6.29), VRX.TO: 152.69 (+8.64)
Why Valeant Isn’t Enron -- or Like Any Other Drug Stock
at The Street - Fri Oct 23, 10:55AM CDT
Whether the allegations against Valeant are true or not, they shouldn't be tainting most other biotech and drug stocks. That's because Valeant is in its own unique universe.
VRX: 116.16 (+6.29), PFE: 34.05 (+0.72), ABBV: 50.34 (+2.07), LLY: 78.31 (+1.33), BMY: 65.16 (+1.98)
Horizon Pharma Counters Depomed Hit On Drug Pricing
at Investor's Business Daily - Fri Oct 23, 10:47AM CDT
Specialty drugmaker Horizon Pharma's (HZNP) battered stock rose sharply Friday as the company issued a statement countering its takeover target Depomed 's (DEPO) charges regarding its drug-pricing policy. Horizon has been in hot water since Monday,...
ESRX: 85.11 (+2.42), VRX: 116.16 (+6.29), HZNP: 17.06 (+3.94), CVS: 103.95 (-0.34), DEPO: 16.94 (+1.53)
Dow 30 Stock Roundup: 3M, Boeing, GE Beat on Earnings, American Express Misses Estimates
Swarup Gupta - Zacks Investment Research - Fri Oct 23, 10:39AM CDT
The Dow experienced another mixed week, dominated by tech, biotech and healthcare stocks.
KO: 42.79 (-0.45), MMM: 155.79 (-0.21), GE: 29.51 (-0.07), VRX: 116.16 (+6.29), AXP: 74.59 (+2.09), IBM: 144.68 (+0.59), UTX: 100.62 (+0.83), MCD: 112.59 (+1.72), CAT: 71.75 (+0.87), BA: 146.70 (+0.39), VZ: 46.16 (+0.27), TRV: 112.28 (-0.04)
Early Market Euphoria Has Cooled Off
at The Street - Fri Oct 23, 10:25AM CDT
But there are a lot of dip buyers out there.
AMZN: 599.03 (+35.12), GE: 29.51 (-0.07), VRX: 116.16 (+6.29), AXP: 74.59 (+2.09), SKX: 31.64 (-14.55), T: 33.74 (-0.22), SPY: 207.51 (+2.25), IBM: 144.68 (+0.59), SRCL: 120.31 (-28.73), MCD: 112.59 (+1.72), GM: 35.95 (+0.53), GOOGL: 719.33 (+38.19), MSFT: 52.87 (+4.84)
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action against Valeant Pharmaceutical International, Inc. and Lead Plaintiff Deadline
PR Newswire - Fri Oct 23, 9:00AM CDT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a securities class action has been filed in the United States District Court for the District of New Jersey on behalf of those who purchased shares of Valeant Pharmaceuticals International, Inc. ("Valeant" or the "Company" (NYSE: VRX), during the period between February 23, 2015 and October 20, 2015 inclusive. (the "Class Period" .
VRX: 116.16 (+6.29), VRX.TO: 152.69 (+8.64)
Global Real Estate and Pharmaceuticals: 2 ETFs to Watch on Outsized Volume
Zacks Equity Research - Zacks Investment Research - Fri Oct 23, 8:17AM CDT
IFGL and IHE saw massive trading volume in Thursday's trading session
IHE: 150.89 (+5.83), VRX: 116.16 (+6.29), SPY: 207.51 (+2.25), IFGL: 29.71 (+0.24), QQQ: 112.78 (+3.07), TXN: 58.98 (+0.89), DIA: 176.37 (+1.57), MCD: 112.59 (+1.72)
Hagens Berman Announces Investigation of Valeant Pharmaceuticals International, Inc. Relating to Accounting Irregularities
Business Wire - Fri Oct 23, 7:30AM CDT
Hagens Berman Sobol Shapiro LLP is investigating shareholder losses related to the allegations that Valeant (NYSE:VRX) may have issued misleading information to investors about the nature of their relationship with Philidor Rx Services. If you have losses from your investments in Valeant or have knowledge relevant to the investigation, contact Hagens Berman Partner Reed Kathrein, who is leading the firm's investigation, by calling (510) 725-3000, emailing valeant@hbsslaw.com or visiting http://hb-securities.com/investigations/valeant.
VRX: 116.16 (+6.29), VRX.TO: 152.69 (+8.64)
Europe's Biggest Bank Considers Moving Headquarters to the U.S.
at The Street - Fri Oct 23, 4:30AM CDT
And four other things you need to know now.
TSLA: 209.09 (-2.63), VRX: 116.16 (+6.29), HSBC: 39.91 (+0.64), GOOGL: 719.33 (+38.19), TWTR: 30.28 (+1.13)
ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Valeant Pharmaceuticals International, Inc. and Encourages Shareholders to Contact the Firm
Business Wire - 28 mins ago
Goldberg Law PC (www.Goldberglawpc.com) announces that a class action lawsuit has been filed in the United States District Court for the District of New Jersey against Valeant Pharmaceuticals International, Inc. ("Valeant" or the "Company"
(NYSE: VRX), for alleged violations of the federal securities laws. Investors who purchased or otherwise acquired shares between February 23, 2015 and October 20, 2015, are advised to contact the firm in advance of the lead plaintiff motion deadline. VRX: 116.16 (+6.29), VRX.TO: 152.69 (+8.64)
Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Valeant Pharmaceuticals International, Inc. (VRX)
GlobeNewswire - 44 mins ago
Gainey McKenna & Egleston announces that a class action lawsuit has been filed in the United States District Court for the District of New Jersey on behalf of all persons or entities that purchased the securities of Valeant Pharmaceuticals International, Inc. ("Valeant" or the "Company"
(NYSE:VRX) between February 23, 2015 and October 20, 2015 (the "Class Period" , alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the "Complaint" . VRX: 116.16 (+6.29), VRX.TO: 152.69 (+8.64)
EQUITY ALERT: Rosen Law Firm Expands Class Period in Securities Class Action Lawsuit Against Valeant Pharmaceuticals International, Inc.
Business Wire - 2 hrs 37 mins ago
Rosen Law Firm, a global investor rights law firm, announces that it has filed a class action lawsuit on behalf of purchasers of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) securities from February 28, 2014 through October 21, 2015, both dates inclusive (the "Class Period"
. The lawsuit seeks to recover damages for Valeant investors under the federal securities laws. VRX: 116.16 (+6.29), VRX.TO: 152.69 (+8.64)
Bernstein Liebhard LLP Investigates Claims on Behalf of Those Who Invested in Valeant Pharmaceuticals International, Inc.
PR Newswire - Fri Oct 23, 4:00PM CDT
Bernstein Liebhard LLP is investigating whether Valeant Pharmaceuticals International, Inc. ("Valeant" or the "Company"
(NYSE: VRX) violated the federal securities laws by making misstatements concerning the Company's business. The investigation concerns whether Valeant and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. VRX: 116.16 (+6.29), VRX.TO: 152.69 (+8.64)
Few Can Grab Big-Cap Coattails
at The Street - Fri Oct 23, 3:15PM CDT
Another good day, but it's a narrow market.
AMZN: 599.03 (+35.12), GE: 29.51 (-0.07), VRX: 116.16 (+6.29), AXP: 74.59 (+2.09), SKX: 31.64 (-14.55), VFC: 63.75 (-9.46), WHR: 145.90 (-13.91), T: 33.74 (-0.22), SPY: 207.51 (+2.25), IBM: 144.68 (+0.59), TGT: 72.94 (-4.17), SRCL: 120.31 (-28.73), MCD: 112.59 (+1.72), GM: 35.95 (+0.53), GOOGL: 719.33 (+38.19), MSFT: 52.87 (+4.84)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Valeant Pharmaceuticals International, Inc. of Pendency of Class Action Lawsuit and a Lead Plaintiff Deadline of December 21, 2015 - VRX
GlobeNewswire - Fri Oct 23, 3:06PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
VRX: 116.16 (+6.29), VRX.TO: 152.69 (+8.64)
It's Been a Great Week, but Don't Get Cocky
at The Street - Fri Oct 23, 2:30PM CDT
There's some good news in the headlines, but potential threats lurk.
AMZN: 599.03 (+35.12), VRX: 116.16 (+6.29), SONC: 27.74 (+0.04), IBM: 144.68 (+0.59), P: 12.39 (-6.80), FB: 102.19 (+2.52), WYNN: 67.60 (+4.42), DIS: 113.09 (-0.16), MCD: 112.59 (+1.72), GOOGL: 719.33 (+38.19), WDC: 69.34 (-0.62), SNDK: 78.37 (+1.28)
Valeant Shares on a Slide, To Host Emergency Board Meeting
Zacks Equity Research - Zacks Investment Research - Fri Oct 23, 2:20PM CDT
Investors have raised questions regarding the accounting and business practices of Valeant (VRX), particularly its relationship with specialty pharmacies.
VRX: 116.16 (+6.29), NVO: 55.72 (+2.07), ANAC: 102.90 (+10.87)
Valeant Pharmaceuticals (VRX) Stock Rebounds Ahead of Conference Call
at The Street - Fri Oct 23, 12:31PM CDT
Valeant Pharmaceuticals (VRX) stock is rallying in midday trading on Friday, ahead of a conference call on Monday addressing Citron Research's allegations.
VRX: 116.16 (+6.29)
Clarification: Earns-Valeant Pharmaceuticals
AP - Fri Oct 23, 12:01PM CDT
QUEBEC, Quebec (AP) — An Oct. 19 story on Valeant Pharmaceuticals International Inc.'s quarterly earnings generated by Automated Insights failed to mention the month in which the company's current quarter ends. It ends in December.
VRX: 116.16 (+6.29), VRX.TO: 152.69 (+8.64)
Shareholder Alert: Morganti Legal Announces Investigation of Valeant Pharmaceuticals International Inc. (VRX)
CNW Group - Fri Oct 23, 10:57AM CDT
Morganti Legal, a cross-border law firm focused on representing investors, has commenced an investigation into potential violations of securities laws by Valeant Pharmaceuticals International Inc. (TSX and NYSE: "VRX"
in respect of allegations that Valeant may have released materially misleading business information to the investing public including potentially inflating revenues by recording intercompany sales in its revenue figures. VRX: 116.16 (+6.29), VRX.TO: 152.69 (+8.64)
Why Valeant Isn’t Enron -- or Like Any Other Drug Stock
at The Street - Fri Oct 23, 10:55AM CDT
Whether the allegations against Valeant are true or not, they shouldn't be tainting most other biotech and drug stocks. That's because Valeant is in its own unique universe.
VRX: 116.16 (+6.29), PFE: 34.05 (+0.72), ABBV: 50.34 (+2.07), LLY: 78.31 (+1.33), BMY: 65.16 (+1.98)
Horizon Pharma Counters Depomed Hit On Drug Pricing
at Investor's Business Daily - Fri Oct 23, 10:47AM CDT
Specialty drugmaker Horizon Pharma's (HZNP) battered stock rose sharply Friday as the company issued a statement countering its takeover target Depomed 's (DEPO) charges regarding its drug-pricing policy. Horizon has been in hot water since Monday,...
ESRX: 85.11 (+2.42), VRX: 116.16 (+6.29), HZNP: 17.06 (+3.94), CVS: 103.95 (-0.34), DEPO: 16.94 (+1.53)
Dow 30 Stock Roundup: 3M, Boeing, GE Beat on Earnings, American Express Misses Estimates
Swarup Gupta - Zacks Investment Research - Fri Oct 23, 10:39AM CDT
The Dow experienced another mixed week, dominated by tech, biotech and healthcare stocks.
KO: 42.79 (-0.45), MMM: 155.79 (-0.21), GE: 29.51 (-0.07), VRX: 116.16 (+6.29), AXP: 74.59 (+2.09), IBM: 144.68 (+0.59), UTX: 100.62 (+0.83), MCD: 112.59 (+1.72), CAT: 71.75 (+0.87), BA: 146.70 (+0.39), VZ: 46.16 (+0.27), TRV: 112.28 (-0.04)
Early Market Euphoria Has Cooled Off
at The Street - Fri Oct 23, 10:25AM CDT
But there are a lot of dip buyers out there.
AMZN: 599.03 (+35.12), GE: 29.51 (-0.07), VRX: 116.16 (+6.29), AXP: 74.59 (+2.09), SKX: 31.64 (-14.55), T: 33.74 (-0.22), SPY: 207.51 (+2.25), IBM: 144.68 (+0.59), SRCL: 120.31 (-28.73), MCD: 112.59 (+1.72), GM: 35.95 (+0.53), GOOGL: 719.33 (+38.19), MSFT: 52.87 (+4.84)
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action against Valeant Pharmaceutical International, Inc. and Lead Plaintiff Deadline
PR Newswire - Fri Oct 23, 9:00AM CDT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a securities class action has been filed in the United States District Court for the District of New Jersey on behalf of those who purchased shares of Valeant Pharmaceuticals International, Inc. ("Valeant" or the "Company"
(NYSE: VRX), during the period between February 23, 2015 and October 20, 2015 inclusive. (the "Class Period" . VRX: 116.16 (+6.29), VRX.TO: 152.69 (+8.64)
Global Real Estate and Pharmaceuticals: 2 ETFs to Watch on Outsized Volume
Zacks Equity Research - Zacks Investment Research - Fri Oct 23, 8:17AM CDT
IFGL and IHE saw massive trading volume in Thursday's trading session
IHE: 150.89 (+5.83), VRX: 116.16 (+6.29), SPY: 207.51 (+2.25), IFGL: 29.71 (+0.24), QQQ: 112.78 (+3.07), TXN: 58.98 (+0.89), DIA: 176.37 (+1.57), MCD: 112.59 (+1.72)
Hagens Berman Announces Investigation of Valeant Pharmaceuticals International, Inc. Relating to Accounting Irregularities
Business Wire - Fri Oct 23, 7:30AM CDT
Hagens Berman Sobol Shapiro LLP is investigating shareholder losses related to the allegations that Valeant (NYSE:VRX) may have issued misleading information to investors about the nature of their relationship with Philidor Rx Services. If you have losses from your investments in Valeant or have knowledge relevant to the investigation, contact Hagens Berman Partner Reed Kathrein, who is leading the firm's investigation, by calling (510) 725-3000, emailing valeant@hbsslaw.com or visiting http://hb-securities.com/investigations/valeant.
VRX: 116.16 (+6.29), VRX.TO: 152.69 (+8.64)
Europe's Biggest Bank Considers Moving Headquarters to the U.S.
at The Street - Fri Oct 23, 4:30AM CDT
And four other things you need to know now.
TSLA: 209.09 (-2.63), VRX: 116.16 (+6.29), HSBC: 39.91 (+0.64), GOOGL: 719.33 (+38.19), TWTR: 30.28 (+1.13)
